Sanofi Makes Changes to Executive Committee

Published on: 

Sanofi announced that it is making several changes to its executive committee, effective June 1, 2016.

On May 23, 2016, Oliver Brandicourt, MD, CEO of Sanofi, announced that the company has plans to make changes to its executive committee effective June 1, 2016. In a press announcement, the company said it would be making the changes to the committee in alignment with its 2020 Strategic Roadmap. The executive committee will be include the following members:

  • Olivier Charmeil, executive vice-president and general manager, General Medicines and Emerging Markets

  • Jérôme Contamine, executive vice-president, Finance

  • Peter Guenter, executive vice-president and general manager, Diabetes & Cardiovascular

  • Carsten Hellmann, executive vice-president and general manager of Merial (until Dec. 31, 2016)

  • Karen Linehan, executive vice-president, Legal Affairs and General Counsel

  • David Loew, executive vice-president and general manager of Sanofi Pasteur

  • Philippe Luscan, executive vice-president, Global Industrial Affairs

  • Muzammil Mansuri, PhD, executive vice-president, Strategy & Business Development

  • David Meeker, MD, executive vice-president and general manager of Sanofi Genzyme

  • Ameet Nathwani, MD, executive vice-president, Medical Affairs

  • Roberto Pucci, executive vice-president, Human Resources

  • Elias Zerhouni, MD, president, Global Research & Development.

Sanofi also announced that Suresh Kumar, executive vice-president, external affairs will be returning to the United States. He will represent the company’s interests in the US until the end of the year. Oliver Brandicourt will serve as acting head of External Affairs until a replacement for Kumar is found. Two other Sanofi executives will also be leaving the company: Pascale Witz, executive vice-president, Diabetes & Cardiovascular, and Carsten Hellmann, executive vice-president, Merial.

Sanofi also said it plans to name an executive vice-president, Consumer Healthcare (CHC) who will be a member of the Executive Committee. This person will lead a newly created CHC global business unit, which will be formed following the anticipated completion of the business swap announced in December 2015 that consists of Sanofi’s animal health business Merial and Boehringer Ingelheim’s consumer healthcare business.

Source: Sanofi